-

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming healthcare conferences.

Forte will be presenting at the Guggenheim 2nd Annual Healthcare Innovation Conference at the InterContinental Boston in Boston MA on Mon, Nov 10 at 3:30-3:55 PM ET.

On Nov. 12 at 2:00-2:20 PM ET, Forte will present at the virtual TD Cowen Immunology and Inflammation Summit.

Additionally on Dec 4 at 11:15-11:35 AM ET, Forte will be presenting at the 8th Annual Evercore Healthcare Conference in Coral Gables FL at the Loews Hotel.

Source: Forte Biosciences, Inc.

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

Industry:

Forte Biosciences, Inc.

NASDAQ:FBRX
Release Versions
English

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

More News From Forte Biosciences, Inc.

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc.  (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-...

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value = 0.020) Response to FB102 was observed early, with statistically significant improvements observed by the day 64 visit (p=0.023)...

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its c...
Back to Newsroom